Cancer Biology Research Center (CBC)
The mission of the Cancer Biology Research Center (CBC) is to advance understanding, prevention, diagnosis, and treatment of cancer by generating new knowledge in cancer biology and therapy and by participating in the application of this knowledge to translational and clinical cancer research.
Research Groups and Infrastructures
The CBC is currently directed by Dr. M.-H. Wang with eighteen members across SOP, SOM, and Amarillo VA Medical Center. The members are located either in SOP main building or in adjacent Amarillo Research Building. Current members include: Drs. Fakhrul Ahsan, Zonghan Dai, Jayarama Gunaje, Cheng Jiang, Lili Li, Xinli Liu, Paul Lockman, Junxuan Lu, U.S. Rao, Quentin Smith, Sanjay Srivastava, K.S. Srivenugopal, Yunxia Tao, Wei Wang, Stephen Wright, Jinhui Zhang, Ruiwen Zhang, and Yong Zhang. In addition, more than 15 postdoctoral fellows and 35 graduated students are working with the CBC members in various cancer-related projects.
Based on members’ background and expertise, the CBC has been organized into three project targeted units: i) Cancer Chemoprevention: studying natural products and chemicals that potentially prevent tumor initiation and progression. ii) Cancer Biology & Pathogenesis: studying multi-signaling cascades that regulate cancer malignancy and phenotype. iii) Cancer Therapeutics & Therapy: developing potential anti-cancer therapeutics and studying mechanisms to overcome cancer drug resistance. The CBC also has an Advanced Cancer Cell Image/Analysis core with following major equipment: FACSAria flow-cytometer with cell sorting, Olympus multiphoton laser scanning microscope, Caliper IVIS/Lumina XR animal image system, GeneAMP5700 real-time PCR; Bio-Rad 5000 VersaDoc Image System; Leica TCS-SL Confocal Spectral Microscope System, Olympus DSU Confocal microscope; GenePix Pro4200A DNA/Protein Microarray (ARB); MSL-HPLC, and other necessary equipment. These advanced instruments allow the CBC members and their associates in-depth analysis of molecular events occurred during cancer progression and drug treatment.
Background & Accomplishments
The CBC was formed in 1999 with common interests and goals shared by several faculty members in the School of Pharmacy. The goal is to determine molecular mechanisms of cancer malignancy with specific aims to develop advanced anti-cancer therapeutics for effective clinical treatment.
Over the last 10 years, the CBC the significantly expanded into three major cancer research areas: Chemoprevention, Cancer Biology, and Experimental Therapeutics. More than 20 research grants with total support of >$10 million research dollars were obtained from NIH, DOD, CPRIT, and other funding agencies. Currently, the CBC has more than 1.5 million dollars annually, which support various biomedical and pharmaceutical research projects.This is a remarkable achievement reflecting the members’ effort and dedication considering the current funding scenario.
Through intensive collaborative and innovative research, the CBC members have made numerous discoveries and published more than 100 articles in highly peer-reviewed journals including Cancer Research, Clinical Cancer Research, Oncogene, Molecular Cancer Therapeutics, Molecular Cancer, Molecular Pharmaceutics, JBC, Carcinogenesis, and other peer-reviewed journals. The CBC members also serve in various national committees, such as NIH Study Sections, DOD grant review panels, various journal editorial boards, and act as organizers & sections chairs for various local, national, and international cancer-related conferences
In summary the CBC is currently a vital research component in the School of Pharmacy and a major research force in the TTU system wide cancer research community.